Answers are grounded in this paper and cite their sources.
Hypoalbuminemia has been repeatedly linked to increased non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT); a recent analysis also suggested an association with relapse risk. To evaluate the relationship between hypoalbuminemia, NRM, and relapse, we assessed its prognostic role in 1258 adults with MDS (myelodysplastic neoplasm)/AML or AML allografted while in remission between 2006 and 2023. After multivariable adjustment, low pre-HCT serum albumin levels were statistically significantly associated with NRM (hazard ratio [HR] = 0.67, p = 0.028), relapse-free survival (RFS; HR = 0.73, p = 0.005), and overall survival (OS; HR = 0.72, p = 0.007) but not relapse (HR = 0.77, p = 0.070). A day-28 landmark analysis showed day +28 hypoalbuminemia to be associated with NRM (HR = 0.31, p < 0.001), RFS (HR = 0.67, p < 0.001), and OS (HR = 0.52, p < 0.001) but not relapse (HR = 1.08, p = 0.6). Together, our data indicate that pre- and post-HCT serum albumin levels are independently associated with NRM and survival in AML patients undergoing allogeneic HCT.
No takes yet. Share an insight, caveat, or question.
Orvain et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: